This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pankuch, G. A.
Right arrow Articles by Appelbaum, P. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pankuch, G. A.
Right arrow Articles by Appelbaum, P. C.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, October 2003, p. 3270-3274, Vol. 47, No. 10
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.10.3270-3274.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Activities of a New Oral Streptogramin, XRP 2868, Compared to Those of Other Agents against Streptococcus pneumoniae and Haemophilus Species

Glenn A. Pankuch,1 Linda M. Kelly,1 Gengrong Lin,1 Andre Bryskier,2 Catherine Couturier,2 Michael R. Jacobs,3 and Peter C. Appelbaum1*

Department of Pathology, Hershey Medical Center, Hershey, Pennsylvania 17033,1 Aventis Pharma, Romainville, France,2 Case Western Reserve University, Cleveland, Ohio 441063

Received 17 June 2003/ Returned for modification 11 July 2003/ Accepted 14 July 2003

MIC methodology was used to test the antibacterial activity of XRP 2868, a new oral combination of two semisynthetic streptogramins, RPR 132552A and RPR 202868, compared to activities of other antibacterial agents against pneumococci, Haemophilus influenzae, and Haemophilus parainfluenzae. For 261 pneumococci, XRP 2868 and pristinamycin MICs were similar, irrespective of penicillin G and erythromycin A susceptibilities (MIC at which 50% of isolates were inhibited [MIC50], 0.25 µg/ml; MIC90, 0.5 µg/ml), while quinupristin/dalfopristin had MICs which were 1 to 2 dilutions higher. Single components of both XRP 2868 and quinupristin/dalfopristin had higher MICs. Erythromycin A, azithromycin, clarithromycin, and clindamycin MICs were higher for penicillin G-intermediate and -resistant than -susceptible pneumococci. Against 150 H. influenzae strains, all compounds tested had unimodal MIC distributions. XRP 2868 had an overall MIC50 of 0.25 µg/ml and an MIC90 of 1.0 µg/ml, with no differences between ß-lactamase-positive, ß-lactamase-negative, and ß-lactamase-negative ampicillin-resistant strains. Of note was the similarly low activity of one of its components, RPR 132552A. Pristinamycin and quinupristin/dalfopristin had MICs of 0.125 to 8.0 µg/ml; quinupristin alone had MICs of 8.0 to >64.0 µg/ml, and dalfopristin had MICs of 1.0 to >64.0 µg/ml. Erythromycin A, azithromycin, and clarithromycin had modal MICs of 4.0, 1.0, and 8.0 µg/ml, respectively. MICs of all compounds against H. parainfluenzae were 1 to 2 dilutions higher than against H. influenzae. XRP 2868 showed potent activity against pneumococci and Haemophilus strains irrespective of their susceptibility to other agents.

* Corresponding author. Mailing address: Department of Pathology, Hershey Medical Center, P.O. Box 850, Hershey, PA 17033. Phone: (717) 531-5113. Fax: (717) 531-7953. E-mail: pappelbaum{at}psu.edu.

Antimicrobial Agents and Chemotherapy, October 2003, p. 3270-3274, Vol. 47, No. 10
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.10.3270-3274.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Korczynska, M., Mukhtar, T. A., Wright, G. D., Berghuis, A. M. (2007). Structural basis for streptogramin B resistance in Staphylococcus aureus by virginiamycin B lyase. Proc. Natl. Acad. Sci. USA 104: 10388-10393 [Abstract] [Full Text]  
  • Pankuch, G. A., Hoellman, D., Bryskier, A., Lowther, J., Appelbaum, P. C. (2006). Effects of Various Media on the Activity of NXL103 (Formerly XRP 2868), a New Oral Streptogramin, against Haemophilus influenzae. Antimicrob. Agents Chemother. 50: 3914-3916 [Abstract] [Full Text]  
  • Dupuis, M., Leclercq, R. (2006). Activity of a New Oral Streptogramin, XRP2868, against Gram-Positive Cocci Harboring Various Mechanisms of Resistance to Streptogramins. Antimicrob. Agents Chemother. 50: 237-242 [Abstract] [Full Text]  
  • Andes, D., Craig, W. A. (2006). Pharmacodynamics of a New Streptogramin, XRP 2868, in Murine Thigh and Lung Infection Models. Antimicrob. Agents Chemother. 50: 243-249 [Abstract] [Full Text]  
  • Eliopoulos, G. M., Ferraro, M. J., Wennersten, C. B., Moellering, R. C. Jr. (2005). In Vitro Activity of an Oral Streptogramin Antimicrobial, XRP2868, against Gram-Positive Bacteria. Antimicrob. Agents Chemother. 49: 3034-3039 [Abstract] [Full Text]  
  • Goldstein, E. J. C., Citron, D. M., Merriam, C. V., Warren, Y. A., Tyrrell, K. L., Fernandez, H. T., Bryskier, A. (2005). Comparative In Vitro Activities of XRP 2868, Pristinamycin, Quinupristin-Dalfopristin, Vancomycin, Daptomycin, Linezolid, Clarithromycin, Telithromycin, Clindamycin, and Ampicillin against Anaerobic Gram-Positive Species, Actinomycetes, and Lactobacilli. Antimicrob. Agents Chemother. 49: 408-413 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»